Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Given that Amateur:
Why is our PPS so dismal?
Granted, if just one of them comes thru and past the goalpost, we win very nicely.
But it's been a long wait.
"Check the latest deck
http://www.biolinerx.com/uploaded/BLRX%20corporate%20presentation%20(June-17)%20(final).pdf
3 collaborations with top BP multiple trials ongoing
Cash on hand - $ 57 million
Market cap - $ 80 million
Many trials sponsored by BP
A very good 2018 play "
Sorry Lakingsphan:
If that's true, some of them must be pretty big!
Remarkably elastic cat Jack.
12% just today!
If you are truly out as you said, shouldn't you just sit quietly until it rises enough to re-establish your former short position?
looking at the recent post history;
gotta wonder if we are the last 2 stockholders?
If so, they'd better be nice to us!
Hot diggity!..We just might make $2!!
Kinda thrilling!
Good attitude, hope you are right....
But neither of us knows diddle.
( Is that a double negative?)
If the market agreed, we wouldn't be up 5.4% just now....in a rational market, grin.
Hi Masters.
You may be right; but i've been stampeded into selling cheap several times when i should have just sat on it and gone and done something constructive.
But then i've always been slow on the trigger finger.
Down 5% today on news of Amazon's buying Whole Foods.
Just checked the GILD site and see they have 9 , Ph 3 trials, and 26 ph 2 clinical trials in progress or being submitted for approval.
It's almost as cheap as when i bought it some time back.
I feel kinda dumb for not taking profits at the peak.
Every time it drops i pick up a bit more stock...Same with IONS
Blue,we both are in that kind of pain, This has long been my largest holding,
but blaming posters over inflates our influence by orders of magnatude.
Might just as well blame unreasonable speculation or expectations unlinked to the temporal reality.
Clinical trials in cancer research spans years and the members of this board have trouble hanging in for weeks and months in large part.
Kick back and watch the soiled shorts dance, they're entertaining and short lived.
We agree on this blueye, it'd certainly help.
Dan certainly saved our butts and is a great improvement over his predecessor;
but now we need a different kind of CEO who can take our constructs over the FDA goal line in a strategically efficient manner.
Oh sure Gantor;
EBIX comes to mind, but there have been others. EBIX was driven down to $4(?) on rumors and short attacks and recovered to it's present $54.
We are in a new era of deregulation and it's reasonable to expect much more of this sort of thing.
We can despair, or we can view it as a gift and buy the lows, sit tight and profit later.
Just plain Wrong Hornet.
Our volatile SP is characteristic of a modest, cash flow negative bio between major clinical trials/ approval news releases. It's happened to us before.
Us long suffering longs have repeatedly weathered this old yo-yo ride,
impatiently waiting for solid PH 3 results and FDA or EU approval.
The extremity of the yo-yo ride is exacerbated by deregulation.
Selling out after all our years of hard won scientific and clinical trials progress, would be simply stupid.
As we plummet towards the bottom, it's the time to buy like crazy.
Remember,
"Buy low, sell high"!
Look, this has happened to us before and we recovered.
We always slump between major clinical trials success releases.
This board is populated by a bunch of manic-depressives, seems like.
We had wildly built up our expectations, in part because of a lack of company transparency allowed speculation to run rampant.
When the premature and unsupported expectations weren't met, the wind went out of our sails.
IF we get EU marketing approval...we'll all be kicking ourselves for missing this
JUICY buying opportunity!
That's the risk with small, cash flow negative bios, generally.
Pacb markets to research oriented organizations primarily. Most of those are dependent on research grants to a greater or lesser degree.
The electorate voted into office ( maybe) an anti-science and research government. They value short term profits over all else That bodes ill for us invested here and the nation as a whole in the long run.
The Chinese are playing the long game and continue to eat our lunch.
I figure to just hunker down and hope it all blows over.
That's the risk with small, cash flow negative bios, generally.
Pacb markets to research oriented organizations primarily. Most of those are dependent on research grants to a greater or lesser degree.
The electorate voted into office ( maybe) an anti-science and research government. They value short term profits over all else That bodes ill for us invested here and the nation as a whole in the long run.
The Chinese are playing the long game and continue to eat our lunch.
I figure to just hunker down and hope it all blows over.
HDW:
Dual is nifty,
but AXAL has complete PH2 clinical trials under it's belt right now so the values aren't at all equivalent.
Unless all we are offering is more hollow hope.
More likely the FDA leaked that one.
"IMO ADXS leaks inside info like an old rowboat, this is why we saw for example volume selling before retail investors knew about the clinical hold, when clearly some big players found out early.
So it is possible that this decision was known by certain hedge funds leading up to Investor Day, and the volume in the days leading up could have been positioning to use it as a takedown. Just like the clinical hold news. "
JB:
If we can get RU marketing approval for AXAL, produce it ourselves and put it out there boasting an unprecedented 39% survival rate...Folks will come to us to buy it in growing numbers.
With that cash flow to fund the dual trials, we will have a solid product with solid patent and IP before the protection on AXAL runs out.
"Respectfully disagree. NEO is the only ADXS program where a non-non-profit organization has made a material financial commitment. "
Didn't say it wasn't worth pursuing...I just don't think it's developed and proven enough to get all excited about yet..
NEO hasn't cured anybody of cancer, yet.
Possible marketing approval has to be at least 10 years away. I'm too old to wait for it.
Gantor:
The go-it-alone posture ( which i advocated too) made sense when it didn't yet cost around a billion bucks to get FDA approval.
We had the cash and were in a position to do that, and didn't inexplicably.
The iron is no longer hot and hitting it only makes little dents.
We don't have the $ to put it back in the forge now.
" No transparency and Dans gotta go"
....Ummmm, OK....
Got somebody better we can afford who wants the job?
Hi FBG:
Regardless of the questionable way he got those shares from us, he owns them and the drop in SP is a drop in his net worth, plain and simple.
He did not cause the low SP on purpose, it hurts the CEO too.
Again, let's hope he's adroitly playing the long game.
ADXS offers diddle for transparency,
and as a shareholder i can't help but to ask why.
I noticed.
Ah well, Hope didn't spring eternal after all.
How kind of you...please be so gracious as to arrange that outcome good Doctor.
Hi again Dew:
No drug was ever approved for use on humans by the FDA based solely on mouse trial results....they aren't "real life" in this context...Only a preliminary indicator that is often unproductive.
We know exactly how much BP values NEO.
Given all of our Ph 2 affirmed trial results, Neo isn't a significant part of our true value in my book.....yet.
Hello Sam:...erm....condolences? (wry grin).
Certainly, compared to T Moore, doc is a splendid CEO. He was just plain painful.
ADXS has long been my largest holding...more than a bit ill advised admittedly.
The real influence of my voice, all our voices, is minuscule. My opinion won't pull the SP down a whole penny.
When a share holders sees a better way to proceed or a strategic weakness, it's right and proper for them to speak up, loud and clear. That's what discussion boards are for. It's a democracy and everyone gets to shoot off their mouths.
Like you, i'm in this for the long haul and i don't much care about the short term SP....It;s just noise when viewed with proper perspective.
The shorts and traders are mere, short lived parasites...fleas.
We have made some progress with our science and trials but not as fast as our IP has been aging out and our competitors advancing.
I disagree on the financials...We should have been dumping every penny into clinical trials all along. We had enough to run a Phase 3 a few years back and didn't. The Ph 3 we are running isn't the one most likely to show great results and win approval....in my opinion.
As for talking down the company...I'm not a positive thinker, have a sour disposition by nature and harsh experience. I think positive thinkers are deluded and dangerous...OK, they're funny too.
Doc has a huge vested interest Bking.
We can only hope that he is playing a long game in a manner concealed from us.
An exception might be EU approval.
Substitute "prescient" for "smart" and i'll agree.
The only way we will see a decent and enduring SP revival lies just where it always has...In strong phase 3 clinical trials results.
We still don't have any of those.
Our clinical trial strategy remains a major weakness.
Sam K:
FBG has major skin in this game and has for many years.
Us long time investors have earned the right to criticize management as we have been committed to ADXS considerably longer than management has been here.
OK Gantor; You have an argument there.
How do we take advantage of that?
"Have you learned yet that obsessing over DOC is keeping you oblivious to how real pros run the market on individual stocks? Take off your 100 share investor tinfoil hat and start paying attention to the brutal effectiveness of wall st pros at work. Hint - it has nothing to do with DOC's options or RSUs"
You seem to be primarily addressing short term SP flux.
How DOC runs the company and rewards himself affects the SP long term and that's what concerns many of us.
Marc:
I've raised that question myself in the past.
My guess is that the patents have expired and that once it's FDA approved, they'd only get 7 years or so of IP protection
Running a strong enough ph 3 clinical trial is wildly expensive now and the FDA is fickle and even more politically influenced that it was.
" If AXAL results are so good, then why has NO BP made a move to buy out or merge with ADXS? These monster BPs are a lot wiser than the hope & prayer ADXS shareholders & BP emphatically chose NO DEAL with ADXS for AXAL. In addition, BP refuses to even provide upfront cash to ADXS when they do a collaboration with AXAL."
Free...I thought so too and bet big on that when oil was well over $100/bbl and wprt was over $14.
As long as diesel is cheap, ain't gonna happen real quickly.
Disagree Marc;
"The EU is a sure thing to approve AXAL for production & sale with no proof that AXAL works?"
WE DO have several AXAL clinical trials showing pretty good results!
Now they may not be sufficient for EU approval yet.....But thousands of women are dying every year and our 40% survival rate is the best bet around presently.
Not approving it is inhumane.
Thanks Ignatius:
My wise Mother-in-law (RIP) said that the stock holders were a lot like a coop full of old hens...Easily excited into flapping, squawking and running to and fro by any smallest thing.
Ignatius: Because the company lacks transparency for us SH, we tend to fill that void with speculation and false expectations, much like BS Skinner's pigeons.
Then when our speculative wishes don't come true, our hearts fall and drag the SP down with it.
We are following the SP charts from a focal length of 2" and that makes every little bump or jiggle seem enormous.
This is a long term bet and watching the minute to minute SP is crazy-making.
CattDogg:
They're NOT failures that were highlighted.
But they failed to meet our shareholders expectations for so many years,
expectations that management raised;
that they seem like failures.
"Yeah, kinda stupid to have an analyst investor day to highlight all your failures!"